StO2 Performance Measured on Admission to the Emergency Department in the Assessment of Drug Poisoning

Percentage of Oxygen Saturation of Haemoglobin in Tissues (StO2) Performance Measured on Admission to the Emergency Department in the Assessment of Drug Poisoning

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01861262

Acronym

IMACS

Enrollment

300

Registered

2013-05-23

Start date

2013-04-30

Completion date

2014-02-28

Last updated

2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Poisoning

Keywords

emergency, drug poisoning, StO2 measurement, blood pressure, hemodynamic failure

Brief summary

The primary purpose of the protocol is to evaluate the StO2 performance measured at the admission to the emergency department to identify hemodynamic failure at the admission or within the first three hours of monitoring patients with drug poisoning. The study hypotheses are: * The early detection of hypoperfusion by StO2, essential to prevent the development of collapse. * To limit hemodynamic failure effects, reduce morbidity and mortality of drug poisoning, hospital stay and cost.

Detailed description

The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.

Interventions

DEVICEMeasurement of StO2

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* admitted to the emergency department, * whose pattern of hospitalization is drug poisoning, defined on data from the patient's interrogation or his family if the patient is not able to answer, * Written informed consent signed by the patient or, if he's unable to sign, by a companion, * Affiliated to medical insurance

Exclusion criteria

* Patients without thenar eminence or having a disease of the thenar, * Refusal to participate in the study, * Participation in another biomedical research, * Patient under guardianship, trusteeship or judicial protection, * Pregnant women or nursing mothers

Design outcomes

Primary

Measure	Time frame
StO2 performance measured to identify hemodynamic failure.	Outcome measure is assessed during three hours after the admission to the emergency department.

Secondary

Measure	Time frame
StO2 distribution	Outcome measure is assessed during three hours after the admission to the emergency department.
StO2 threshold value to predict the onset of hemodynamic failure	Outcome measure is assessed during three hours after the admission to the emergency department.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026